| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
|
Medicine details |
|
| Medicine name | edoxaban (Lixiana®) |
| Formulation | 15 mg, 30 mg and 60 mg film-coated tablet |
| Reference number | 2789 |
| Indication | Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults |
| Company | Daiichi Sankyo UK Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/05/2015 |
| NICE guidance | TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |